Alchemab Therapeutics

Alchemab Therapeutics is a next-generation biopharmaceutical company that harnesses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies. By analyzing patient antibody repertoires from individuals who show unexpected resistance to disease (resilient individuals), the company identifies novel drug targets and therapeutics for hard-to-treat conditions. The company utilizes a proprietary AI-enabled platform, often referred to as the 'DataCube,' which integrates deep B-cell sequencing, machine learning, and lab-based protein science. Its pipeline focuses primarily on neurodegenerative diseases, oncology, immunology, and metabolic conditions, aiming to translate natural human resilience into protective therapies for broader patient populations.